CTLA4 and neoplasm: Additional immunotherapeutics that could augment OVs include inhibitors of programed cell death protein 1 (PD-1) or cytotoxic T lymphocyte-associated protein 4 interactions, monoclonal antibodies that block tumor growth, tyrosine kinase inhibitors, cytokines that stimulate inflammation, and pro-apoptotic drugs [78].